Astria Therapeutics (NASDAQ:ATXS) Shares Cross Above 50-Day Moving Average – What’s Next?

Astria Therapeutics, Inc. (NASDAQ:ATXS) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $11.51 and traded as high as $12.47. Astria Therapeutics shares last traded at $11.87, with a volume of 356,408 shares traded.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer raised their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. Finally, TD Cowen initiated coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price target for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Trading Up 3.1 %

The firm has a market capitalization of $669.76 million, a P/E ratio of -5.16 and a beta of 0.71. The stock has a 50 day simple moving average of $11.51 and a 200-day simple moving average of $10.53.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). As a group, sell-side analysts expect that Astria Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after buying an additional 480,184 shares in the last quarter. Tidal Investments LLC purchased a new stake in Astria Therapeutics in the 1st quarter worth approximately $1,664,000. Sofinnova Investments Inc. purchased a new stake in Astria Therapeutics in the 2nd quarter worth approximately $552,000. ClariVest Asset Management LLC bought a new stake in Astria Therapeutics during the 2nd quarter worth approximately $731,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares in the last quarter. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.